Sandoz launches authorized generic version of EXFORGE® in the US

Princeton, New Jersey, March 31, 2015 – Sandoz today announced the US market introduction of amlodipine and valsartan combination tablets, a generic version of EXFORGE® made by Novartis.

Amlodipine and valsartan tablets are a combination of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB).

Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure:

  • in patients not adequately controlled on monotherapy with a DHP CCB or an ARB
  • …
/by

Sandoz launches authorized generic version of EXFORGE® in the US

Princeton, New Jersey, March 31, 2015 – Sandoz today announced the US market introduction of amlodipine and valsartan combination tablets, a generic version of EXFORGE® made by Novartis.

Amlodipine and valsartan tablets are a combination of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB).

Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure:

  • in patients not adequately controlled on monotherapy with a DHP CCB or an ARB
  • …
/by

Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland

  • Sandoz launches 50-250 and 50-500µg dosage forms in Portugal and Ireland
  • Innovative inhaler offers asthma and COPD patients a new therapeutic option
  • Now available to patients in 14 countries, as global roll-out continues apace

Holzkirchen, March 11, 2015 – Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

AirFluSal, which was first approved in Denmark, has now been launched in a …

/by

Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland

  • Sandoz launches 50-250 and 50-500µg dosage forms in Portugal and Ireland
  • Innovative inhaler offers asthma and COPD patients a new therapeutic option
  • Now available to patients in 14 countries, as global roll-out continues apace

Holzkirchen, March 11, 2015 – Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

AirFluSal, which was first approved in Denmark, has now been launched in a …

/by

FDA approves first biosimilar Zarxio™ (filgrastim-sndz) from Sandoz

  • Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA
  • Zarxio is approved for all indications included in the reference product’s (NEUPOGEN®) label
  • Approval paves way for greater access to high-quality biologics in the US and underscores Sandoz global leadership in biosimilars

Holzkirchen, March 06, 2015 – Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved ZarxioTM (filgrastim-sndz) for all …

/by

FDA approves first biosimilar Zarxio™ (filgrastim-sndz) from Sandoz

  • Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA
  • Zarxio is approved for all indications included in the reference product’s (NEUPOGEN®) label
  • Approval paves way for greater access to high-quality biologics in the US and underscores Sandoz global leadership in biosimilars

Holzkirchen, March 06, 2015 – Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved ZarxioTM (filgrastim-sndz) for all …

/by

Novartis announces completion of transactions with GSK

  • Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business
  • Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics
  • Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small molecules, positioning Novartis as a preferred partner for combination agents
  • Transactions expected to immediately lift core margins and further support overall …
/by

Sandoz announces training program for midwives in Ethiopia, to reduce maternal and newborn mortality

  • Approximately 400 mothers and newborns die in Ethiopia each day1,2 partly due to health workers’ limited knowledge in the area of obstetrics
  • Enhancing medical knowledge and skills of health workers helps reduce maternal and newborn mortality
  • Sandoz is committed to increasing access to high-quality, affordable medicines, as well as healthcare services and education for mothers and children

Holzkirchen, Germany, March 2, 2015 – Sandoz today announced the launch of a new program, New Life & New Hope, to improve maternal and …

/by